Home > Healthcare > Pharmaceuticals > Finished Drug Form > Urothelial Cancer Drugs Market

Urothelial Cancer Drugs Market Share

Report ID: GMI9754
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Urothelial Cancer Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture advanced urothelial cancer drugs products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The market players are actively adopting a multi-pronged approaches to address the rising demand for urothelial cancer drugs.

Urothelial Cancer Drugs Market Companies

Prominent players operating in the urothelial cancer drugs industry are as mentioned below:

AstraZeneca Plc
Bristol Myers Squibb
Eisai Co. Ltd.
Exelixis, Inc.
F. Hoffmann La Roche Ltd.
Gilead Science, Inc.
Johnson & Johnson (Janssen Biotech)
Merck & Co. Inc
Merck KGaA
Novartis AG
Pfizer, Inc.
UroGen Pharma, Inc

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global urothelial cancer drugs market was valued at USD 3.2 billion in 2023 and is anticipated to grow at 12.1% CAGR during 2024-2032, driven by rising prevalence of urothelial cancer, particularly bladder cancer.

The urothelial carcinoma segment of the market recorded a revenue of USD 1.7 billion in 2023, owing to its high prevalence.

North America urothelial cancer drugs market secured 40.5% revenue share in 2023 and is expected to dominate through 2032, owing to high levels of awareness about cancer and robust screening programs.

Gilead Science, Inc, Johnson & Johnson (Janssen Biotech), Merck & Co. Inc, Merck KGaA, Novartis AG, Pfizer, Inc, and UroGen Pharma, Inc among others.